首页 > 最新文献

Journal of Diabetology最新文献

英文 中文
Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials 替西帕肽作为2型糖尿病患者的一种新的治疗选择:一项对1-5项试验亚组的汇总分析
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_16_23
M. Abdalla, Ireneous N. Soyiri, S. Atkin, T. Sathyapalan
{"title":"Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: A pooled analysis of subgroups of SURPASS 1-5 trials","authors":"M. Abdalla, Ireneous N. Soyiri, S. Atkin, T. Sathyapalan","doi":"10.4103/jod.jod_16_23","DOIUrl":"https://doi.org/10.4103/jod.jod_16_23","url":null,"abstract":"","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79224634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Papular lesions in a diabetic patient with COVID-19: A case report from India 糖尿病合并COVID-19患者丘疹病变:印度1例报告
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_70_22
Ashish S. Dengra, Jigyasa Dengra, F. Farishta, Ramchandani Gd
{"title":"Papular lesions in a diabetic patient with COVID-19: A case report from India","authors":"Ashish S. Dengra, Jigyasa Dengra, F. Farishta, Ramchandani Gd","doi":"10.4103/jod.jod_70_22","DOIUrl":"https://doi.org/10.4103/jod.jod_70_22","url":null,"abstract":"","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77218853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucagon in the gut – brain axis 胰高血糖素在肠脑轴
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_103_23
Rakesh M Parikh, Banshi Saboo, Viswanathan Mohan, Abdul Basit, Amit Gupta, Jayant K Panda, Mithun Bhartia, Pinar Topsever
The intricate relationship between the gut and the brain has long captured the imagination of scientists, philosophers, and clinicians alike. Over the past few decades, research has unveiled a complex and bidirectional communication network that connects these seemingly distinct organs, giving rise to the concept of the gut–brain axis. This axis represents a dynamic and multifaceted system through which the gut and the brain exchange signals, impacting not only digestive processes but also a wide array of physiological and neurological functions. From influencing appetite and mood to playing a role in metabolic regulation, the gut–brain axis has emerged as a crucial nexus in understanding human health and well-being. This chapter delves into the intricate mechanisms that underlie the gut–brain axis, exploring its components and pathways with a special focus on the role played by glucagon. By unraveling the mysteries of this axis, we gain valuable insights into how our body’s diverse systems collaborate to maintain a delicate balance and how disturbances within this axis can contribute to a range of health conditions.
肠道和大脑之间错综复杂的关系长期以来一直吸引着科学家、哲学家和临床医生的想象力。在过去的几十年里,研究揭示了一个复杂的双向通信网络,它连接着这些看似不同的器官,从而产生了肠脑轴的概念。这个轴代表了一个动态的、多方面的系统,通过这个系统,肠道和大脑交换信号,不仅影响消化过程,还影响一系列广泛的生理和神经功能。从影响食欲和情绪到在代谢调节中发挥作用,肠脑轴已经成为理解人类健康和幸福的关键纽带。本章深入研究肠脑轴背后的复杂机制,探索其组成部分和途径,特别关注胰高血糖素所起的作用。通过解开这个轴的奥秘,我们获得了宝贵的见解,了解我们身体的不同系统如何合作来维持微妙的平衡,以及这个轴内的干扰如何导致一系列健康状况。
{"title":"Glucagon in the gut – brain axis","authors":"Rakesh M Parikh, Banshi Saboo, Viswanathan Mohan, Abdul Basit, Amit Gupta, Jayant K Panda, Mithun Bhartia, Pinar Topsever","doi":"10.4103/jod.jod_103_23","DOIUrl":"https://doi.org/10.4103/jod.jod_103_23","url":null,"abstract":"The intricate relationship between the gut and the brain has long captured the imagination of scientists, philosophers, and clinicians alike. Over the past few decades, research has unveiled a complex and bidirectional communication network that connects these seemingly distinct organs, giving rise to the concept of the gut–brain axis. This axis represents a dynamic and multifaceted system through which the gut and the brain exchange signals, impacting not only digestive processes but also a wide array of physiological and neurological functions. From influencing appetite and mood to playing a role in metabolic regulation, the gut–brain axis has emerged as a crucial nexus in understanding human health and well-being. This chapter delves into the intricate mechanisms that underlie the gut–brain axis, exploring its components and pathways with a special focus on the role played by glucagon. By unraveling the mysteries of this axis, we gain valuable insights into how our body’s diverse systems collaborate to maintain a delicate balance and how disturbances within this axis can contribute to a range of health conditions.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135662400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prof. M. Viswanathan: The pride of Asia in diabetology M. Viswanathan教授:亚洲糖尿病学的骄傲
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_108_23
Satyavani Kumpatla, Vijay Viswanathan, Ambady Ramachandran, Viswanathan Mohan
Dear Editor, Prof. M. Viswanathan (Prof. MV) was not just a doyen in the field of diabetes but also an astute clinician, teacher, researcher, and administrator. He made substantial contributions to diabetes care and research for nearly five decades. He was one of the most internationally recognized research scientists in India of his time. Prof. MV published more than 250 peer-reviewed research papers in prestigious national and international journals. His work propelled India to the forefront of diabetes care and research, and he played a pivotal role in elevating the nation’s status in this field. Born on August 26, 1923, in Kerala, India to Mr. A. K. Menon and Dr. M. Madhavi Amma (who was one of the first doctors of Kerala), Prof. MV’s career in medicine was greatly influenced by his mother. He pursued medicine at Stanley Medical College, Madras graduating in 1946, and worked as a House Physician. At a time, when diabetes was not regarded as a special field of study, he established the first organized diabetes clinic in India in 1948 at the Stanley Medical College. His dedication led to his promotion as Hon. Asst. Prof of Medicine and later as Hon. Prof of Medicine at the same college. In 1952, he married Sarada, who provided unwavering support throughout his life. Prof. MV voluntarily left government service with a view to setting up a hospital and research center devoted to clinical research in diabetes, the first of its kind in India. He also built up his private practice as a full-time Diabetologist. His achievements include the prestigious Dr.B.C.Roy National Award in 1982 for the development of the specialty of diabetology in India by the Medical Council of India. He has the unique honor of being the organizing secretary of three successive Association of Physicians of India (API) conferences. He held the posts of President, Association of Physicians of India, and President of the Scientific Section of the Diabetes Association of India with great distinction. He was also a member of the American Diabetes Association, British Diabetic Association, International Diabetes Federation, European Association for Study of Diabetes (EASD), and the Research Society for Study of Diabetes in India (RSSDI). At his center, Prof. MV created a modern reference library with well-organized resources for diabetes education and research. He also maintained a unique medical records system which served as a database for most of his long-term research findings. Many institutions sought his guidance in setting up modern and well-organized record-keeping departments. Prof. MV research efforts garnered numerous national and international honors and awards. He organized scientific conferences in India and also presented his research work at seminars and conferences worldwide. His primary objectives were to ensure high-quality diabetes research in India and more importantly to prevent and conquer diabetes. He pursued these goals relentlessly and with a missionary z
尊敬的编辑:M. Viswanathan教授(Prof. MV)不仅是糖尿病领域的元老,也是一位精明的临床医生、教师、研究员和管理者。在近50年的时间里,他为糖尿病的治疗和研究做出了重大贡献。他是当时印度最受国际认可的研究科学家之一。他在国内外知名期刊上发表了250多篇经同行评议的研究论文。他的工作将印度推向了糖尿病护理和研究的前沿,他在提升印度在这一领域的地位方面发挥了关键作用。梅农于1923年8月26日出生在印度喀拉拉邦,父母是A. K. Menon先生和M. Madhavi Amma博士(他是喀拉拉邦最早的医生之一)。他在马德拉斯斯坦利医学院攻读医学,1946年毕业,并担任住院医生。当时,糖尿病还没有被视为一个特殊的研究领域,他于1948年在斯坦利医学院建立了印度第一个有组织的糖尿病诊所。他的奉献精神使他晋升为荣誉助理医学教授,后来又成为同一所学院的荣誉医学教授。1952年,他与萨拉达结婚,萨拉达在他的一生中给予了他坚定的支持。MV教授自愿离开政府部门,成立了一家医院和研究中心,致力于糖尿病的临床研究,这是印度第一家此类医院。他还建立了自己的私人诊所,成为一名全职糖尿病专家。他的成就包括1982年由印度医学委员会颁发的著名的b.c. roy博士国家奖,以表彰他在印度糖尿病专科的发展。他有幸连续三次担任印度医师协会(API)会议的组织秘书。他曾担任印度医师协会主席和印度糖尿病协会科学分会主席,并取得了巨大的成就。他也是美国糖尿病协会、英国糖尿病协会、国际糖尿病联合会、欧洲糖尿病研究协会(EASD)和印度糖尿病研究学会(RSSDI)的成员。在他的中心,MV教授创建了一个现代化的参考图书馆,其中有组织良好的糖尿病教育和研究资源。他还拥有一个独特的医疗记录系统,作为他大部分长期研究成果的数据库。许多机构寻求他的指导,建立了现代化和组织良好的记录部门。他的研究工作获得了许多国家和国际上的荣誉和奖项。他在印度组织了科学会议,并在世界各地的研讨会和会议上介绍了他的研究工作。他的主要目标是确保印度高质量的糖尿病研究,更重要的是预防和征服糖尿病。直到1996年3月1日去世,他一直坚持不懈地追求这些目标。在印度,MV教授被公认并最终被称为“糖尿病学之父”。M. Viswanathan教授的研究历程在2型糖尿病的自然历史中,大多数个体都经历了一个葡萄糖调节受损的阶段,最终发展为糖尿病。1954年,Fajans和Conn首次将“糖尿病前期状态”确定为2型糖尿病的前兆。[1]他们将可的松GTT描述为一种检测糖尿病前期状态的可能方法。[2]早在1959年,MV教授就开始了这方面的研究工作。1962年,一项精心设计的研究聚焦于糖尿病患者的亲属,将他们与没有亲属患有糖尿病的对照组进行比较,在类固醇给药后对他们进行葡萄糖耐量试验,结果显示有糖尿病家族史的人,特别是30岁以下的人,血糖异常反应更高。该研究还考虑了肥胖的影响,并将研究结果与1954年至1961年的西方文献进行了比较。这项研究开创了一种识别未来糖尿病风险个体的方法,最终指导MV教授的糖尿病预防工作。[3]MV教授坚信糖尿病是可以预防的,并强调了个人和社区预防策略的重要性。他强调了糖尿病的基本风险因素,这些因素最终导致糖尿病的发展。遗传被确定为一个关键的风险因素,重点关注糖尿病患者的近亲和后代。与遗传因素相比,环境因素是可以改变的,它起着关键作用。其他风险因素,如肥胖、重复怀孕、缺乏体育活动和压力也得到了解决。筛查高危人群可以采取有效的预防措施。 他的观察结果使他相信预防糖尿病的必要性,并探索了阻止这一病理过程进展的方法和手段。[4-6]他强调需要通过初级预防努力认识和扭转糖尿病的自然历史。对后代荷尔蒙谱的研究提供了非常有趣和有用的信息。研究结果揭示了β细胞活性的早期异常。20世纪80年代初,他对胰岛素和c肽水平的研究为以后的研究奠定了基础。这些水平是在口服糖耐量试验中测量的,表明糖耐量受损(IGT)和糖尿病患者的β细胞功能降低,同时肝脏胰岛素提取减少。[7]其他研究人员在西方人群中也报告了类似的发现。1983年Rossell等[8]提出肥胖患者肝脏胰岛素提取减少。Bonora等[9]的另一项研究也表明,IGT中外周高胰岛素血症是胰腺分泌过多和肝脏胰岛素提取减少的结果。MV教授关于预防方面的最后一篇文章强调了减肥对于维持正常葡萄糖耐量的重要性,即使对于有强烈糖尿病家族史的非肥胖个体也是如此。他强调了体育锻炼和合理饮食在降低糖尿病风险方面的作用。[10]MV教授在倡导2型糖尿病预防方面远远领先于他的时代,甚至在NDDG和WHO定义IGT之前,就在葡萄糖耐受不良的早期迹象中提倡生活方式干预。MV教授的开创性研究彻底改变了糖尿病的营养研究。印度人的饮食以谷物为主,富含碳水化合物。当时在印度,人们认为糖尿病患者应该完全不吃米饭。MV教授发现,许多患者不能长期坚持规定的饮食改变。因此,他提出了限制卡路里高碳水化合物高纤维饮食(HCHF)的概念,允许患者遵循他们通常的饮食模式,以达到更好的饮食依从性和患者合作,但限制和避免游离糖。他证明了南印度人吃米饭但限制卡路里的饮食对糖尿病患者来说是理想的。这是MV教授在糖尿病营养学研究方面的重大研究贡献。MV教授注意到我国人民的饮食缺乏蛋白质。他提倡在他们的饮食中加入豆类和豆类形式的植物蛋白来增加蛋白质。这不仅使食物更加均衡,而且在短时间内实现了血糖控制。他创新的饮食策略实现了血糖和血脂的控制,打破了之前的观念。这种饮食模式现在被认为是糖尿病患者更可行的饮食。MV教授广泛研究了2型糖尿病的家族聚集性,强调了遗传对疾病患病率的影响。[11]他早期的研究分析了4000名2型糖尿病患者的亲属数量和分类,发现33.9%的研究参与者有糖尿病家族史,突出了糖尿病的家族聚集性。MV教授的另一项研究涉及对2600名患有糖尿病的夫妻的研究。[12]该研究显示了开创性的结果:当父母双方都患有糖尿病时,近62%的后代有患糖尿病的风险,而当父母只有一方患有糖尿病时,这一风险为22%。他与英国研究人员合作进行了先进的复杂分离遗传分析,为确定印度人群中的糖尿病易感基因铺平了道路。这些观察结果对寻找与2型糖尿病发病机制有关的基因具有重要意义。糖尿病的缓解期可以定义为血糖水平恢复到正常水平并且不需要抗糖尿病治疗的时期。糖尿病缓解的概念最近得到了广泛的认可。因此,令人惊讶的是,MV教授早在1987年就认识到了“糖尿病缓解”的概念。[13]他的研究强调了生活方式改变和医疗干预在实现缓解中的作用,为糖尿病的自然历史提供了有价值的见解。总而言之,MV教授对糖尿病领域的深刻贡献至今仍然有效,他对糖尿病研究的远见卓识产生了持久的影响。他对初级预防、创新饮食干预以及家族聚集和临床管理的开创性研究的重视,极大地推动了该领域的发展,并有助于我们对糖尿病的理解。
{"title":"Prof. M. Viswanathan: The pride of Asia in diabetology","authors":"Satyavani Kumpatla, Vijay Viswanathan, Ambady Ramachandran, Viswanathan Mohan","doi":"10.4103/jod.jod_108_23","DOIUrl":"https://doi.org/10.4103/jod.jod_108_23","url":null,"abstract":"Dear Editor, Prof. M. Viswanathan (Prof. MV) was not just a doyen in the field of diabetes but also an astute clinician, teacher, researcher, and administrator. He made substantial contributions to diabetes care and research for nearly five decades. He was one of the most internationally recognized research scientists in India of his time. Prof. MV published more than 250 peer-reviewed research papers in prestigious national and international journals. His work propelled India to the forefront of diabetes care and research, and he played a pivotal role in elevating the nation’s status in this field. Born on August 26, 1923, in Kerala, India to Mr. A. K. Menon and Dr. M. Madhavi Amma (who was one of the first doctors of Kerala), Prof. MV’s career in medicine was greatly influenced by his mother. He pursued medicine at Stanley Medical College, Madras graduating in 1946, and worked as a House Physician. At a time, when diabetes was not regarded as a special field of study, he established the first organized diabetes clinic in India in 1948 at the Stanley Medical College. His dedication led to his promotion as Hon. Asst. Prof of Medicine and later as Hon. Prof of Medicine at the same college. In 1952, he married Sarada, who provided unwavering support throughout his life. Prof. MV voluntarily left government service with a view to setting up a hospital and research center devoted to clinical research in diabetes, the first of its kind in India. He also built up his private practice as a full-time Diabetologist. His achievements include the prestigious Dr.B.C.Roy National Award in 1982 for the development of the specialty of diabetology in India by the Medical Council of India. He has the unique honor of being the organizing secretary of three successive Association of Physicians of India (API) conferences. He held the posts of President, Association of Physicians of India, and President of the Scientific Section of the Diabetes Association of India with great distinction. He was also a member of the American Diabetes Association, British Diabetic Association, International Diabetes Federation, European Association for Study of Diabetes (EASD), and the Research Society for Study of Diabetes in India (RSSDI). At his center, Prof. MV created a modern reference library with well-organized resources for diabetes education and research. He also maintained a unique medical records system which served as a database for most of his long-term research findings. Many institutions sought his guidance in setting up modern and well-organized record-keeping departments. Prof. MV research efforts garnered numerous national and international honors and awards. He organized scientific conferences in India and also presented his research work at seminars and conferences worldwide. His primary objectives were to ensure high-quality diabetes research in India and more importantly to prevent and conquer diabetes. He pursued these goals relentlessly and with a missionary z","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135703814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy of Tadalafil and Tadalafil + Dapoxetine in managing sexual dysfunction in individuals with type-2 diabetes mellitus: A clinical study 他达拉非及他达拉非+达泊西汀治疗2型糖尿病患者性功能障碍的临床研究
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_123_22
V. Chavda, S. Jha, T. Gandhi, A. Patel, Hiren Raninga, Amol Chaudhari, D. Hasnani
Objective: The present study was aimed to evaluate effect of metabolic parameters on erectile dysfunction (ED) in individuals with type-2 diabetes mellitus (T2DM) and to assess the efficacy of Tadalafil and Tadalafil + Dapoxetine combination. Materials and Methods: A prospective, observational, cross-sectional, bicentric study included 216 males with T2DM who are not treated with phosphodiesterase 5 inhibitors and without chronic kidney disease. The data were obtained from demographic questionnaire, clinical laboratory reports of glycometabolic parameters namely body mass index (BMI), hemoglobin A1c (HbA1c), testosterone, vitamin B12 (VitB12), and lipid profile and analyses of the International Index of Erectile Function (IIEF) questionnaire. The effect of physical and metabolic parameters on IIEF sub-domains namely erectile function; orgasmic function; sexual desire (SD); intercourse satisfaction; and overall satisfaction was evaluated. A statistical significance was evaluated using χ2 test or t-test. Result: SD is most significantly lower in subjects with imbalanced physiological and metabolic characteristics including BMI, HbA1c, testosterone, VitB12, triglyceride, high-density lipoprotein, and low-density lipoprotein. Both Tadalafil and Tadalafil + Dapoxetine significantly improved almost all IIEF parameters without any pronounced effect of either. Similarly, both the treatments improved all the IIEF parameters for subjects with high BMI except for SD. In subjects with cardiac comorbidities, the use of either treatment significantly enhanced all the IIEF scores. Conclusion: The findings of this study outline the need of careful examination of sexual dysfunction in healthcare clinics for diabetic individuals. An imbalanced physiological and metabolic profile leads to ED in individuals with T2DM. Additionally, the presence of co-morbidities further elevates the odds of ED prevalence. The treatment with Tadalafil and Tadalafil + Dapoxetine drug combination shows promising results in improving the ED but a study with larger pool of subjects is needed to determine the additional benefits of Dapoxetine.
目的:本研究旨在评价代谢参数对2型糖尿病(T2DM)患者勃起功能障碍(ED)的影响,并评价他达拉非与他达拉非+达泊西汀联合用药的疗效。材料和方法:一项前瞻性、观察性、横断面、双中心研究包括216名未接受磷酸二酯酶5抑制剂治疗且无慢性肾脏疾病的男性2型糖尿病患者。数据来自人口统计问卷、临床实验室报告的糖代谢参数,即体重指数(BMI)、血红蛋白A1c (HbA1c)、睾酮、维生素B12 (VitB12)和血脂,以及国际勃起功能指数(IIEF)问卷的分析。生理和代谢参数对IIEF子域即勃起功能的影响;性高潮功能;性欲(SD);性交满意度;然后对总体满意度进行评估。采用χ2检验或t检验评价差异有统计学意义。结果:BMI、HbA1c、睾酮、维生素b12、甘油三酯、高密度脂蛋白和低密度脂蛋白等生理代谢特征不平衡的受试者SD最显著降低。他达拉非和他达拉非+达泊西汀均可显著改善几乎所有IIEF参数,但均无明显影响。同样,两种治疗方法均改善了高BMI受试者除SD外的所有IIEF参数。在患有心脏合并症的受试者中,使用任何一种治疗方法均可显著提高所有IIEF评分。结论:本研究的发现概述了在保健诊所对糖尿病患者进行性功能障碍仔细检查的必要性。生理和代谢失衡导致2型糖尿病患者发生ED。此外,合并症的存在进一步提高了ED患病率的几率。他达拉非和他达拉非+达泊西汀联合治疗在改善ED方面显示出有希望的结果,但需要更大规模的研究来确定达泊西汀的额外益处。
{"title":"The efficacy of Tadalafil and Tadalafil + Dapoxetine in managing sexual dysfunction in individuals with type-2 diabetes mellitus: A clinical study","authors":"V. Chavda, S. Jha, T. Gandhi, A. Patel, Hiren Raninga, Amol Chaudhari, D. Hasnani","doi":"10.4103/jod.jod_123_22","DOIUrl":"https://doi.org/10.4103/jod.jod_123_22","url":null,"abstract":"Objective: The present study was aimed to evaluate effect of metabolic parameters on erectile dysfunction (ED) in individuals with type-2 diabetes mellitus (T2DM) and to assess the efficacy of Tadalafil and Tadalafil + Dapoxetine combination. Materials and Methods: A prospective, observational, cross-sectional, bicentric study included 216 males with T2DM who are not treated with phosphodiesterase 5 inhibitors and without chronic kidney disease. The data were obtained from demographic questionnaire, clinical laboratory reports of glycometabolic parameters namely body mass index (BMI), hemoglobin A1c (HbA1c), testosterone, vitamin B12 (VitB12), and lipid profile and analyses of the International Index of Erectile Function (IIEF) questionnaire. The effect of physical and metabolic parameters on IIEF sub-domains namely erectile function; orgasmic function; sexual desire (SD); intercourse satisfaction; and overall satisfaction was evaluated. A statistical significance was evaluated using χ2 test or t-test. Result: SD is most significantly lower in subjects with imbalanced physiological and metabolic characteristics including BMI, HbA1c, testosterone, VitB12, triglyceride, high-density lipoprotein, and low-density lipoprotein. Both Tadalafil and Tadalafil + Dapoxetine significantly improved almost all IIEF parameters without any pronounced effect of either. Similarly, both the treatments improved all the IIEF parameters for subjects with high BMI except for SD. In subjects with cardiac comorbidities, the use of either treatment significantly enhanced all the IIEF scores. Conclusion: The findings of this study outline the need of careful examination of sexual dysfunction in healthcare clinics for diabetic individuals. An imbalanced physiological and metabolic profile leads to ED in individuals with T2DM. Additionally, the presence of co-morbidities further elevates the odds of ED prevalence. The treatment with Tadalafil and Tadalafil + Dapoxetine drug combination shows promising results in improving the ED but a study with larger pool of subjects is needed to determine the additional benefits of Dapoxetine.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"29 1","pages":"48 - 55"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87149416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of serum galectin-3 levels in patients with gestational diabetes mellitus 妊娠期糖尿病患者血清半乳糖凝集素-3水平的评价
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_84_22
S. Baldane, M. Çelik, M. Korez, Emine Gul Baldane, S. Abuşoğlu, Unlu Ali, S. Ipekci, L. Kebapçılar
Objective: This study was aimed to compare serum galectin-3 (Gal-3) levels in gestational diabetes mellitus (GDM) and healthy pregnant women and to evaluate the relationship between insulin resistance parameters and serum Gal-3 levels. Materials and Methods: Fifty-nine pregnant women who were screened for GDM with oral glucose tolerance tests (OGTT) at the 24th–28th gestational weeks were included in the study. According to the results of OGTT, 34 pregnant women were included in the GDM group and 25 pregnant women were included in the control group. Results: Serum Gal-3 value was found to be similar in the GDM and control group (P < 0.471). However, there was a significant positive association between Gal-3 and fasting insulin (r = 0.509, P < 0.001) and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.479, P < 0.001) in the whole pregnancies, and between Gal-3 levels and fasting insulin (r = 0.608, P < 0.001), HOMA-IR (r = 0.609, P < 0.001), and OGTT 60 min glucose (r = 0.444, P = 0.016) in the GDM patients. Conclusions: There was no difference in the last trimester serum Gal-3 levels between GDM and healthy pregnant women. However, a significant positive correlation was determined between Gal-3 and fasting insulin, HOMA-IR, and OGTT 60 min glucose values in the GDM group, and fasting insulin and HOMA-IR values in whole pregnancies. The results of our study support previous data reporting the relationship between Gal-3 and GDM through insulin resistance.
目的:比较妊娠期糖尿病(GDM)与健康孕妇血清半乳糖凝集素-3 (Gal-3)水平,探讨胰岛素抵抗参数与血清Gal-3水平的关系。材料与方法:采用口服糖耐量试验(OGTT)筛查妊娠期24 ~ 28周GDM的59例孕妇纳入研究。根据OGTT结果,34名孕妇被纳入GDM组,25名孕妇被纳入对照组。结果:GDM组血清Gal-3值与对照组相似(P < 0.471)。然而,在整个妊娠期,Gal-3水平与空腹胰岛素(r = 0.509, P < 0.001)和胰岛素抵抗稳态模型评估(HOMA-IR) (r = 0.479, P < 0.001)呈显著正相关;在GDM患者中,Gal-3水平与空腹胰岛素(r = 0.608, P < 0.001)、HOMA-IR (r = 0.609, P < 0.001)和OGTT 60分钟葡萄糖(r = 0.444, P = 0.016)呈显著正相关。结论:妊娠晚期GDM与健康孕妇血清Gal-3水平无差异。然而,Gal-3与GDM组的空腹胰岛素、HOMA-IR和OGTT 60分钟血糖值以及全妊娠期的空腹胰岛素和HOMA-IR值之间存在显著的正相关。我们的研究结果支持了先前关于Gal-3通过胰岛素抵抗与GDM之间关系的报道。
{"title":"Assessment of serum galectin-3 levels in patients with gestational diabetes mellitus","authors":"S. Baldane, M. Çelik, M. Korez, Emine Gul Baldane, S. Abuşoğlu, Unlu Ali, S. Ipekci, L. Kebapçılar","doi":"10.4103/jod.jod_84_22","DOIUrl":"https://doi.org/10.4103/jod.jod_84_22","url":null,"abstract":"Objective: This study was aimed to compare serum galectin-3 (Gal-3) levels in gestational diabetes mellitus (GDM) and healthy pregnant women and to evaluate the relationship between insulin resistance parameters and serum Gal-3 levels. Materials and Methods: Fifty-nine pregnant women who were screened for GDM with oral glucose tolerance tests (OGTT) at the 24th–28th gestational weeks were included in the study. According to the results of OGTT, 34 pregnant women were included in the GDM group and 25 pregnant women were included in the control group. Results: Serum Gal-3 value was found to be similar in the GDM and control group (P < 0.471). However, there was a significant positive association between Gal-3 and fasting insulin (r = 0.509, P < 0.001) and homeostasis model assessment of insulin resistance (HOMA-IR) (r = 0.479, P < 0.001) in the whole pregnancies, and between Gal-3 levels and fasting insulin (r = 0.608, P < 0.001), HOMA-IR (r = 0.609, P < 0.001), and OGTT 60 min glucose (r = 0.444, P = 0.016) in the GDM patients. Conclusions: There was no difference in the last trimester serum Gal-3 levels between GDM and healthy pregnant women. However, a significant positive correlation was determined between Gal-3 and fasting insulin, HOMA-IR, and OGTT 60 min glucose values in the GDM group, and fasting insulin and HOMA-IR values in whole pregnancies. The results of our study support previous data reporting the relationship between Gal-3 and GDM through insulin resistance.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"55 1","pages":"28 - 33"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79254957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of gamma irradiation on the 24-h glycemic responses of parboiled brown rice diets in Asian Indian adults: A randomized cross-over study γ辐射对亚洲印度成年人半煮糙米饮食24小时血糖反应的影响:一项随机交叉研究
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_81_22
S. Shobana, Rajagopal Gayathri, Mathiyazhagan Jayanthan, V. Sudha, S. Jamdar, N. Malleshi, Kamala Krishnaswamy, Ranjit Mohan Anjana, R. Unnikrishnan, V. Mohan
Background: The nutritional importance of brown rice (BR) is well established. Despite several nutritional benefits of BR, its consumption remains limited due to long cooking time and limited shelf-life. BR can be subjected to processing to improve shelf-life. Gamma irradiation is one such strategy, but it could induce changes in the grain and thus affect its glycemic properties. Aims and objectives: The aim of this study was to look at the 24-h glycemic response of irradiated and non-irradiated BR-based iso-caloric diets in Asian Indians. Methods: Fifteen (mean body mass index: 24 ± 2.6 kg/m2) Asian Indian adults without diabetes, aged 25–39 years, participated in this randomized cross-over study. Iso-caloric diets were prepared with two varieties (ADT 43 and Swarna) of parboiled gamma-irradiated brown rice with 750–820 Gy dosage (IBR) and non-irradiated brown rice (NIBR). After the participants consumed these diets, 24-h glycemic responses were recorded using a continuous glucose monitoring system. The mean positive change from baseline glucose concentration was calculated as the incremental area under the curve (IAUC) for both the diets. Results: The percentage difference in 24-h average IAUC was 10% lower in the IBR diets when compared with NIBR diets, irrespective of the variety of BR (P = 0.56). In the case of ADT 43 rice variety, both IBR and NIBR diets showed similar IAUC (P = 0.68). However, the IBR of Swarna rice variety showed 21% lower IAUC when compared with the NIBR diet (P = 0.21). Comparing the IBR varieties, Swarna showed 21% lower IAUC than ADT 43 (P = 0.21), whereas between NIBR varieties, only 0.79% difference was observed between ADT 43 and Swarna (P = 0.93). Conclusions: Gamma irradiation of parboiled BR did not produce significant differences in the 24-h glycemic responses for BR-based diets. Swarna variety was better than ADT 43 with regard to glycemic response. Judicious application of radiation technology to BR varieties may help in shelf-life extension without affecting the glycemic properties.
背景:糙米(BR)的营养重要性是公认的。尽管BR具有多种营养价值,但由于烹饪时间长,保质期有限,其消费量仍然有限。BR可以经过加工以提高货架期。伽马射线照射就是这样一种策略,但它可能会引起谷物的变化,从而影响其血糖特性。目的和目的:本研究的目的是观察亚洲印度人辐照和未辐照br等热量饮食的24小时血糖反应。方法:15例(平均体重指数:24±2.6 kg/m2)无糖尿病的亚洲印度成年人,年龄25-39岁,参与了这项随机交叉研究。采用剂量为750 ~ 820 Gy的半煮γ辐照糙米(IBR)和未辐照糙米(NIBR)制备等热量饲料(ADT 43和Swarna)。在参与者食用这些饮食后,使用连续血糖监测系统记录24小时的血糖反应。以两种饮食的增量曲线下面积(IAUC)计算与基线葡萄糖浓度相比的平均正变化。结果:无论BR的种类如何,IBR饲粮与NIBR饲粮相比,24小时平均IAUC的百分比差异降低了10% (P = 0.56)。以ADT 43品种为例,IBR和NIBR日粮的IAUC相近(P = 0.68)。与NIBR日粮相比,Swarna水稻品种的IAUC降低了21% (P = 0.21)。与IBR品种相比,Swarna的IAUC比ADT 43低21% (P = 0.21),而在NIBR品种之间,ADT 43与Swarna的IAUC差异仅为0.79% (P = 0.93)。结论:半煮BR的伽马辐射对BR为基础的饮食的24小时血糖反应没有显著差异。在血糖反应方面,Swarna品种优于ADT 43。在不影响升糖性能的前提下,对BR品种合理应用辐射技术可以延长其保质期。
{"title":"Effect of gamma irradiation on the 24-h glycemic responses of parboiled brown rice diets in Asian Indian adults: A randomized cross-over study","authors":"S. Shobana, Rajagopal Gayathri, Mathiyazhagan Jayanthan, V. Sudha, S. Jamdar, N. Malleshi, Kamala Krishnaswamy, Ranjit Mohan Anjana, R. Unnikrishnan, V. Mohan","doi":"10.4103/jod.jod_81_22","DOIUrl":"https://doi.org/10.4103/jod.jod_81_22","url":null,"abstract":"Background: The nutritional importance of brown rice (BR) is well established. Despite several nutritional benefits of BR, its consumption remains limited due to long cooking time and limited shelf-life. BR can be subjected to processing to improve shelf-life. Gamma irradiation is one such strategy, but it could induce changes in the grain and thus affect its glycemic properties. Aims and objectives: The aim of this study was to look at the 24-h glycemic response of irradiated and non-irradiated BR-based iso-caloric diets in Asian Indians. Methods: Fifteen (mean body mass index: 24 ± 2.6 kg/m2) Asian Indian adults without diabetes, aged 25–39 years, participated in this randomized cross-over study. Iso-caloric diets were prepared with two varieties (ADT 43 and Swarna) of parboiled gamma-irradiated brown rice with 750–820 Gy dosage (IBR) and non-irradiated brown rice (NIBR). After the participants consumed these diets, 24-h glycemic responses were recorded using a continuous glucose monitoring system. The mean positive change from baseline glucose concentration was calculated as the incremental area under the curve (IAUC) for both the diets. Results: The percentage difference in 24-h average IAUC was 10% lower in the IBR diets when compared with NIBR diets, irrespective of the variety of BR (P = 0.56). In the case of ADT 43 rice variety, both IBR and NIBR diets showed similar IAUC (P = 0.68). However, the IBR of Swarna rice variety showed 21% lower IAUC when compared with the NIBR diet (P = 0.21). Comparing the IBR varieties, Swarna showed 21% lower IAUC than ADT 43 (P = 0.21), whereas between NIBR varieties, only 0.79% difference was observed between ADT 43 and Swarna (P = 0.93). Conclusions: Gamma irradiation of parboiled BR did not produce significant differences in the 24-h glycemic responses for BR-based diets. Swarna variety was better than ADT 43 with regard to glycemic response. Judicious application of radiation technology to BR varieties may help in shelf-life extension without affecting the glycemic properties.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"43 1 1","pages":"20 - 27"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76914413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health literacy, medication belief, and demographic factors as correlates of medication adherence in person with diabetes mellitus 健康素养、用药信念和人口统计学因素与糖尿病患者服药依从性的关系
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_4_23
O. Olorunfemi
{"title":"Health literacy, medication belief, and demographic factors as correlates of medication adherence in person with diabetes mellitus","authors":"O. Olorunfemi","doi":"10.4103/jod.jod_4_23","DOIUrl":"https://doi.org/10.4103/jod.jod_4_23","url":null,"abstract":"","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88293819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Historical perspectives of glucagon’s discovery and early research 胰高血糖素的发现和早期研究的历史观点
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_107_23
Debashish Brahmachari, Shabeen Naz Masood, Umaira Aziz, Tatjana Milenkovic, Manoj Chawla, A G Unnikrishnan, Sujoy Ghosh, João Raposo, Banshi Saboo, Viswanathan Mohan
Abstract This review article looks at the historical journey of the discovery of glucagon and the initial stages of research that paved the way for a comprehensive understanding of its physiological significance. Glucagon, an essential peptide hormone produced by the pancreas, plays a pivotal role in maintaining glucose homeostasis. Tracing the trajectory of its discovery from its initial identification to the unraveling of its complex functions, this article offers a detailed analysis of the early scientific endeavors, and collaborations that contributed to shaping our understanding of glucagon’s pivotal role. By exploring the historical context, controversies, and advancements, this review sheds light on the evolution of endocrinological knowledge and its profound implications for diabetes research and treatment strategies.
这篇综述文章着眼于胰高血糖素发现的历史历程和研究的初始阶段,为全面了解其生理意义铺平了道路。胰高血糖素是胰腺产生的一种重要的肽激素,在维持葡萄糖稳态中起着关键作用。追溯其发现的轨迹,从最初的鉴定到其复杂功能的解开,本文提供了早期科学努力的详细分析,以及有助于形成我们对胰高血糖素关键作用的理解的合作。本文通过对历史背景、争议和进展的探讨,揭示了内分泌学知识的演变及其对糖尿病研究和治疗策略的深远影响。
{"title":"Historical perspectives of glucagon’s discovery and early research","authors":"Debashish Brahmachari, Shabeen Naz Masood, Umaira Aziz, Tatjana Milenkovic, Manoj Chawla, A G Unnikrishnan, Sujoy Ghosh, João Raposo, Banshi Saboo, Viswanathan Mohan","doi":"10.4103/jod.jod_107_23","DOIUrl":"https://doi.org/10.4103/jod.jod_107_23","url":null,"abstract":"Abstract This review article looks at the historical journey of the discovery of glucagon and the initial stages of research that paved the way for a comprehensive understanding of its physiological significance. Glucagon, an essential peptide hormone produced by the pancreas, plays a pivotal role in maintaining glucose homeostasis. Tracing the trajectory of its discovery from its initial identification to the unraveling of its complex functions, this article offers a detailed analysis of the early scientific endeavors, and collaborations that contributed to shaping our understanding of glucagon’s pivotal role. By exploring the historical context, controversies, and advancements, this review sheds light on the evolution of endocrinological knowledge and its profound implications for diabetes research and treatment strategies.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135703807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Centenary of glucagon discovery and birth centenary of a pioneer in diabetology in India 胰高血糖素发现百年和印度糖尿病学先驱百年诞辰
Pub Date : 2023-01-01 DOI: 10.4103/jod.jod_109_23
Banshi Saboo, Akhtar Hussain, Abdul Basit, Viswanathan Mohan
Dear Editor, We are very happy to present a special issue of the Journal of Diabetology (JOD) which is dedicated to the centenary celebrations of two major events. The year 2023 marks the birth centenary of Prof. M. Viswanathan, considered the “Father of Diabetology in India.” 2023 also marks the centenary of the discovery of the enigmatic hormone, glucagon. To mark these two very special occasions, JOD is proud to present a special tribute to Prof. M. Viswanathan, written by his two sons, Dr. V. Mohan and Dr. Vijay Viswanathan, and his son-in-law, Dr. A. Ramachandran, all of whom were personally mentored by Prof. M. Viswanathan. We dedicate this issue to Prof. M. Viswanathan whose contributions are legendary. He is credited with starting the specialty of Diabetology in India. This year also marks the centenary of the discovery of glucagon, the pancreatic hormone produced by the alpha cells of the islets of Langerhans. To commemorate the centenary of glucagon, we invited specialists from different parts of the world to contribute articles for a special issue dedicated to glucagon. This includes historical aspects, including its discovery, and goes on to describe its increasing role today in the management of both diabetes and obesity. We are very grateful to the authors who have contributed articles for the special issue of JOD at short notice. We do hope you will enjoy reading about this oft-forgotten, but important, hormone, glucagon. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
亲爱的编辑,我们很高兴为大家推出一期特刊《糖尿病学杂志》(JOD),以纪念两项重大事件的百年庆典。2023年是M. Viswanathan教授诞辰100周年,他被认为是“印度糖尿病之父”。2023年也是神秘激素胰高血糖素被发现100周年。为了纪念这两个非常特殊的时刻,JOD很自豪地向M. Viswanathan教授致敬,由他的两个儿子V. Mohan博士和Vijay Viswanathan博士以及他的女婿a . Ramachandran博士撰写,他们都受到M. Viswanathan教授的亲自指导。我们把这一期献给M. Viswanathan教授,他的贡献是传奇的。他被认为是印度糖尿病学专业的开创者。今年也是胰高血糖素发现一百周年,胰高血糖素是由朗格汉斯岛的α细胞产生的胰腺激素。为了纪念胰高血糖素诞生一百周年,我们邀请了来自世界各地的专家为胰高血糖素专刊投稿。这包括历史方面,包括它的发现,并继续描述它今天在糖尿病和肥胖管理中日益重要的作用。我们非常感谢那些在短时间内为《JOD》特刊投稿的作者。我们真的希望你会喜欢阅读这种经常被遗忘,但重要的激素,胰高血糖素。财政支持及赞助无。利益冲突没有利益冲突。
{"title":"Centenary of glucagon discovery and birth centenary of a pioneer in diabetology in India","authors":"Banshi Saboo, Akhtar Hussain, Abdul Basit, Viswanathan Mohan","doi":"10.4103/jod.jod_109_23","DOIUrl":"https://doi.org/10.4103/jod.jod_109_23","url":null,"abstract":"Dear Editor, We are very happy to present a special issue of the Journal of Diabetology (JOD) which is dedicated to the centenary celebrations of two major events. The year 2023 marks the birth centenary of Prof. M. Viswanathan, considered the “Father of Diabetology in India.” 2023 also marks the centenary of the discovery of the enigmatic hormone, glucagon. To mark these two very special occasions, JOD is proud to present a special tribute to Prof. M. Viswanathan, written by his two sons, Dr. V. Mohan and Dr. Vijay Viswanathan, and his son-in-law, Dr. A. Ramachandran, all of whom were personally mentored by Prof. M. Viswanathan. We dedicate this issue to Prof. M. Viswanathan whose contributions are legendary. He is credited with starting the specialty of Diabetology in India. This year also marks the centenary of the discovery of glucagon, the pancreatic hormone produced by the alpha cells of the islets of Langerhans. To commemorate the centenary of glucagon, we invited specialists from different parts of the world to contribute articles for a special issue dedicated to glucagon. This includes historical aspects, including its discovery, and goes on to describe its increasing role today in the management of both diabetes and obesity. We are very grateful to the authors who have contributed articles for the special issue of JOD at short notice. We do hope you will enjoy reading about this oft-forgotten, but important, hormone, glucagon. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.","PeriodicalId":15627,"journal":{"name":"Journal of Diabetology","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135703811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Diabetology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1